Ciprofloxacin monohydrochloride
Based on 57 publication(s) in Google Scholar
Ciprofloxacin (Bay-09867) monohydrochloride is an orally active, blood-brain barrier permeable fluoroquinolone antibacterial agent. Ciprofloxacin monohydrochloride exerts bactericidal effects primarily by inhibiting topoisomerase II and IV. Ciprofloxacin monohydrochloride inhibits the proliferation of human dental pulp stem cells and chondrocytes from young rats, and also activates the Akt signaling pathway and upregulates markers such as β-catenin and Nanog to maintain the morphological characteristics of stem cells. Ciprofloxacin monohydrochloride induces significant neurotoxicity and tissue damage, including reducing serotonin and glutathione levels in the brain, inducing oxidative stress and depression-like behaviors, and causing articular cartilage damage. Ciprofloxacin monohydrochloride can be applied to research related to infections of necrotic young permanent teeth and neurotoxicity.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.86%
- CAS No.: 93107-08-5
- Formule: C17H19ClFN3O3
- Masse moléculaire:367.81
-
Stockage:
4°C, sealed storage, away from moisture and light
* The compound is unstable in solutions, freshly prepared is recommended.
Publications Citing Use of MedChemExpress (MCE) Ciprofloxacin monohydrochloride
More- Nature. 2024 Aug;632(8027):1137-1144. [Abstract]
- Mater Today. 2026 Apr 7;96:103326.
- Nat Cell Biol. 2024 Sep;26(9):1545-1557. [Abstract]
- Nat Commun. 2022 Mar 2;13(1):1116. [Abstract]
- Adv Sci (Weinh). 2020 Jul 21;7(17):2001374. [Abstract]
- Water Res. 2024 Nov 29:271:122885. [Abstract]
- Water Res. 2023 Jul 15:240:120110. [Abstract]
- Chem Eng J. 2025 May 1.
- J Exp Med. 2026 Mar 2;223(3):e20241287. [Abstract]
- NPJ Biofilms Microbiomes. 2025 Mar 7;11(1):40. [Abstract]
- NPJ Biofilms Microbiomes. 2024 Oct 28;10(1):111. [Abstract]
- EBioMedicine. 2022 Apr;78:103943. [Abstract]
- Genome Biol. 2023 Apr 30;24(1):98. [Abstract]
- Food Res Int. 2026 Aug 31:238:119421. [Abstract]
- Emerg Contam. 2026 Feb 23.
- Arch Pharm Res. 2025 Jan;48(1):102-114. [Abstract]
- J Med Chem. 2025 Dec 11;68(23):25274-25289. [Abstract]
- Virulence. 2026 Dec 31;17(1):2646808. [Abstract]
- Virulence. 2024 Dec;15(1):2415952. [Abstract]
- J Agric Food Chem. 2025 Dec 23. [Abstract]
- Anal Chim Acta. 2022 Aug 15:1221:340082. [Abstract]
- Front Microbiol. 2022 Feb 16:12:773664. [Abstract]
- Colloids Surf A Physicochem Eng Asp. 2025 Dec 26;734:139401.
- Arab J Chem. 2024 May, 17, 5, 105745.
- ACS Appl Polym Mater. 2023 Aug 29.
- Molecules. 2023 Jun 8;28(12):4628. [Abstract]
- Int J Antimicrob Agents. 2018 Aug;52(2):269-271. [Abstract]
- PLoS Pathog. 2024 Dec 31;20(12):e1012783. [Abstract]
- Appl Microbiol Biotechnol. 2022 Apr;106(7):2689-2702. [Abstract]
- iScience. 2023 Oct 7;26(11):108158. [Abstract]
- Antimicrob Agents Chemother. 2026 Apr;70(4):e0170625. [Abstract]
- Antimicrob Agents Chemother. 2025 Jul 2;69(7):e0024925. [Abstract]
- J Antimicrob Chemother. 2026 Jun 3;81(7):dkag204. [Abstract]
- Microbiol Spectr. 2025 Jul;13(7):e0307424. [Abstract]
- Microbiol Spectr. 2022 Jun 29;10(3):e0251821. [Abstract]
- Microbiol Spectr. 2022 Feb 23;10(1):e0099121. [Abstract]
- J Antimicrob Chemother. 2020 Jul 1;75(7):1850-1858. [Abstract]
- Microb Pathog. 2024 Jun:191:106666. [Abstract]
- Appl Biochem Biotechnol. 2025 Aug 23. [Abstract]
- Water. 2025 Jun 6.
- Cardiovasc Toxicol. 2024 Sep;24(9):889-903. [Abstract]
- Infect Drug Resist. 2026 May 8;19.
- Infect Drug Resist. 2025 Oct 4:18:5239-5247. [Abstract]
- Eur J Clin Microbiol Infect Dis. 2025 Sep 29. [Abstract]
- Anim Dis. 2021;1(1):26. [Abstract]
- Vet Microbiol. 2024 May:292:110046. [Abstract]
- J Microbiol Methods. 2026 Feb 25:107441. [Abstract]
- Diagn Microbiol Infect Dis. 2026 Feb;114(2):117181. [Abstract]
- bioRxiv. 2026 Jan 19.
- Orebro University. 2024.
- bioRxiv. 2024 Nov 06.
- bioRxiv. 2024 May 10.
- bioRxiv. 2024 Feb 9.
- bioRxiv. 2024 Jan 18.
- Research Square Preprint. 2020 Jun.
- Patent. US20200101105A1.
- Chemosphere. 2019 Jun:225:378-387. [Abstract]
-
Microbiological Assay
-
Microbiological Assay
-
Bio/Physico-chemical Assay
-
Bio/Physico-chemical Assay
-
Others
Voir tous les produits spécifiques à Isoform Antibiotic
MoreVoir tous les produits spécifiques à Isoform Topoisomerase
More
Activité biologique
|
Quinolone |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A-431 | IC50 |
135 μM
Compound: 1
|
Inhibition of human A431 cell proliferation by MTT assay
Inhibition of human A431 cell proliferation by MTT assay
|
[PMID: 19595598] |
| A-431 | IC50 |
137 μM
Compound: Ciprofloxacin
|
Cytotoxicity against human A431 cells assessed as reduction in cell viability by MTT assay
Cytotoxicity against human A431 cells assessed as reduction in cell viability by MTT assay
|
[PMID: 30660827] |
| A-431 | IC50 |
>128 μM
Compound: CFX
|
Anticancer activity against human A-431 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
Anticancer activity against human A-431 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
|
[PMID: 31881454] |
| A549 | IC50 |
280 μM
Compound: 1
|
Antitumor activity against human A549 cells after 5 days by MTT assay
Antitumor activity against human A549 cells after 5 days by MTT assay
|
[PMID: 19595598] |
| A549 | IC50 |
>100 μM
Compound: Ciprofloxacin
|
Antiproliferative activity against human A549 cells after 24 hrs by BrdU incorporation assay
Antiproliferative activity against human A549 cells after 24 hrs by BrdU incorporation assay
|
[PMID: 27555286] |
| A549 | IC50 |
>302 nM
Compound: Ciprofloxacin
|
Antiproliferative activity against human A549 cells after 72 hrs by MTT assay
Antiproliferative activity against human A549 cells after 72 hrs by MTT assay
|
[PMID: 30660827] |
| A549 | IC50 |
0.33 mM
Compound: CFX
|
Antitumor activity against human A549 cells assessed as reduction in cell viability incubated for 4 hrs by MTT assay
Antitumor activity against human A549 cells assessed as reduction in cell viability incubated for 4 hrs by MTT assay
|
[PMID: 31881454] |
| B-cell | IC50 |
123 μM
Compound: ciprofloxacin
|
Antiproliferative activity against Theileria parva-induced proliferation of bovine B lymphocyte assessed as inhibition of [3H]thymidine uptake after 48 hrs
Antiproliferative activity against Theileria parva-induced proliferation of bovine B lymphocyte assessed as inhibition of [3H]thymidine uptake after 48 hrs
|
[PMID: 19075064] |
| CAPAN-1 | IC50 |
>100 μM
Compound: Ciprofloxacin
|
Cytotoxicity against human Capan1 cells assessed as reduction in cell viability by MTT assay
Cytotoxicity against human Capan1 cells assessed as reduction in cell viability by MTT assay
|
[PMID: 30660827] |
| CHO | CC50 |
512 μM
Compound: CPFX
|
Cytotoxicity against CHO cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
Cytotoxicity against CHO cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
|
[PMID: 31525660] |
| CHO | IC50 |
>150 μM
Compound: CFX
|
Cytotoxicity against Chinese hamster CHO cells assessed as reduction in cell viability by MTT assay
Cytotoxicity against Chinese hamster CHO cells assessed as reduction in cell viability by MTT assay
|
[PMID: 31881454] |
| CT26 | IC50 |
0.33 mM
Compound: CFX
|
Antitumor activity against mouse CT26 cells assessed as reduction in cell viability incubated for 4 hrs by MTT assay
Antitumor activity against mouse CT26 cells assessed as reduction in cell viability incubated for 4 hrs by MTT assay
|
[PMID: 31881454] |
| EJ | IC50 |
202 μM
Compound: 1
|
Inhibition of human EJ cell proliferation by MTT assay
Inhibition of human EJ cell proliferation by MTT assay
|
[PMID: 19595598] |
| EJ | IC50 |
137 μM
Compound: Ciprofloxacin
|
Cytotoxicity against human EJ cells assessed as reduction in cell viability by MTT assay
Cytotoxicity against human EJ cells assessed as reduction in cell viability by MTT assay
|
[PMID: 30660827] |
| EJ | IC50 |
>128 μM
Compound: CFX
|
Anticancer activity against human EJ cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
Anticancer activity against human EJ cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
|
[PMID: 31881454] |
| HaCaT | IC50 |
222.1 μM
Compound: CP
|
Cytotoxicity against human HaCaT cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
Cytotoxicity against human HaCaT cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
|
[PMID: 31678743] |
| HBL-100 | IC50 |
10.28 μM
Compound: C; Cip
|
Cytotoxicity against human HBL-100 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
Cytotoxicity against human HBL-100 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
|
[PMID: 34319100] |
| HEK-293T | CC50 |
>60 μg/mL
Compound: Ciprofloxacin
|
Cytotoxicity against HEK293T cells assessed as reduction in cell viability measured after 24 hrs by MTT assay
Cytotoxicity against HEK293T cells assessed as reduction in cell viability measured after 24 hrs by MTT assay
|
[PMID: 27720324] |
| HeLa | IC50 |
120 μg/mL
Compound: Ciprofloxacin
|
Inhibition of metabolic activity in HeLa cells assessed as MTT reduction after 48 hrs
Inhibition of metabolic activity in HeLa cells assessed as MTT reduction after 48 hrs
|
[PMID: 17088489] |
| HeLa | IC50 |
290 μg/mL
Compound: Ciprofloxacin
|
Antiproliferative effect against HeLa cells after 48 hrs
Antiproliferative effect against HeLa cells after 48 hrs
|
[PMID: 17088489] |
| HeLa | IC50 |
800 μM
Compound: 1
|
Inhibition of human HeLa cell proliferation assessed as bromodeoxyuridine incorporation during DNA synthesis after 48 hrs by ELISA
Inhibition of human HeLa cell proliferation assessed as bromodeoxyuridine incorporation during DNA synthesis after 48 hrs by ELISA
|
[PMID: 19595598] |
| HeLa | IC50 |
>100 μM
Compound: Ciprofloxacin
|
Cytotoxicity against human HeLa cells after 24 hrs by LDH release assay
Cytotoxicity against human HeLa cells after 24 hrs by LDH release assay
|
[PMID: 27018907] |
| Hep 3B2 | IC50 |
>100 μM
Compound: Ciprofloxacin
|
Cytotoxicity against human Hep3B cells assessed as reduction in cell viability by MTT assay
Cytotoxicity against human Hep3B cells assessed as reduction in cell viability by MTT assay
|
[PMID: 30660827] |
| HEp-2 | CC50 |
>100 μM
Compound: CIP
|
Cytotoxicity against human Hep2 cell line after 72 hrs
Cytotoxicity against human Hep2 cell line after 72 hrs
|
[PMID: 17228862] |
| HEp-2 | CC50 |
>100 μM
Compound: CIP
|
Cytotoxicity against human Hep2 cells after 72 hrs by alamar blue assay
Cytotoxicity against human Hep2 cells after 72 hrs by alamar blue assay
|
[PMID: 21425851] |
| HEp-2 | CC50 |
>100 μM
Compound: CIP
|
Cytotoxicity against human Hep2 cell line after 72 hrs
Cytotoxicity against human Hep2 cell line after 72 hrs
|
[PMID: 21443219] |
| HepG2 | CC50 |
>100 μM
Compound: CIP
|
Cytotoxicity against human HepG2 cells after 72 hrs
Cytotoxicity against human HepG2 cells after 72 hrs
|
[PMID: 17228862] |
| HepG2 | IC50 |
>0.5 mM
Compound: CPX, B-H
|
Cytotoxicity against human HepG2 cells measured after overnight incubation by MTT assay
Cytotoxicity against human HepG2 cells measured after overnight incubation by MTT assay
|
[PMID: 21855181] |
| HepG2 | IC50 |
>128 μg/mL
Compound: CIP
|
Cytotoxicity against human HepG2 cells after 24 hrs by cell titre-glo assay
Cytotoxicity against human HepG2 cells after 24 hrs by cell titre-glo assay
|
[PMID: 27499455] |
| HepG2 | IC50 |
27 μM
Compound: Ciprofloxacin
|
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 7 days by MTT assay
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 7 days by MTT assay
|
[PMID: 28237557] |
| HepG2 | CC50 |
138.6 μg/mL
Compound: CPX
|
Cytotoxicity in human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by ATP bioluminescence assay
Cytotoxicity in human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by ATP bioluminescence assay
|
[PMID: 30067360] |
| HepG2 | IC50 |
>128 μg/mL
Compound: CIP
|
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability for 24 hrs by Celltiter-Glo assay
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability for 24 hrs by Celltiter-Glo assay
|
[PMID: 35231579] |
| HL-60 | IC50 |
>100 μM
Compound: Ciprofloxacin
|
Cytotoxicity against human HL60 cells assessed as reduction in cell viability by MTT assay
Cytotoxicity against human HL60 cells assessed as reduction in cell viability by MTT assay
|
[PMID: 30660827] |
| HL-60 | IC50 |
>302 nM
Compound: Ciprofloxacin
|
Antiproliferative activity against human HL60 cells after 72 hrs by MTT assay
Antiproliferative activity against human HL60 cells after 72 hrs by MTT assay
|
[PMID: 30660827] |
| HL-60 | IC50 |
≥ 100 μM
Compound: Ciprofloxacin
|
Antiproliferative activity against human HL60 cells by MTT assay
Antiproliferative activity against human HL60 cells by MTT assay
|
[PMID: 30660827] |
| HL-60 | IC50 |
>150 μM
Compound: CFX
|
Cytotoxicity against human HL-60 cells assessed as reduction in cell viability by MTT assay
Cytotoxicity against human HL-60 cells assessed as reduction in cell viability by MTT assay
|
[PMID: 31881454] |
| K562 | IC50 |
>150 μM
Compound: 1
|
Inhibition of human K562 cell proliferation by sulphorodhamine B assay
Inhibition of human K562 cell proliferation by sulphorodhamine B assay
|
[PMID: 19595598] |
| KB | IC50 |
160 μM
Compound: 1
|
Inhibition of human KB cell proliferation by MTT assay
Inhibition of human KB cell proliferation by MTT assay
|
[PMID: 19595598] |
| KB | IC50 |
>128 μM
Compound: CFX
|
Anticancer activity against human KB cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
Anticancer activity against human KB cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
|
[PMID: 31881454] |
| L02 | IC50 |
12.23 μM
Compound: Ciprofloxacin
|
Cytotoxicity against human L02 cells after 72 hrs by CCK-8 assay
Cytotoxicity against human L02 cells after 72 hrs by CCK-8 assay
|
[PMID: 35398730] |
| L02 | IC50 |
4.05 μg/mL
Compound: Ciprofloxacin
|
Cytotoxicity against human L02 cells after 72 hrs by CCK-8 assay
Cytotoxicity against human L02 cells after 72 hrs by CCK-8 assay
|
[PMID: 35398730] |
| L1210 | IC50 |
>100 μM
Compound: Ciprofloxacin
|
Cytotoxicity against mouse L1210 cells assessed as reduction in cell viability by MTT assay
Cytotoxicity against mouse L1210 cells assessed as reduction in cell viability by MTT assay
|
[PMID: 30660827] |
| L1210 | IC50 |
≥ 100 μM
Compound: Ciprofloxacin
|
Antiproliferative activity against mouse L1210 cells by MTT assay
Antiproliferative activity against mouse L1210 cells by MTT assay
|
[PMID: 30660827] |
| L1210 | IC50 |
>150 μM
Compound: CFX
|
Antiproliferative activity against mouse L1210 cells assessed as reduction in cell viability by MTT assay
Antiproliferative activity against mouse L1210 cells assessed as reduction in cell viability by MTT assay
|
[PMID: 31881454] |
| L1210 | IC50 |
>150 μM
Compound: CFX
|
Cytotoxicity against mouse L1210 cells assessed as reduction in cell viability by MTT assay
Cytotoxicity against mouse L1210 cells assessed as reduction in cell viability by MTT assay
|
[PMID: 31881454] |
| L6 | IC50 |
3.3998 μM
Compound: Ciprofloxacin Hydrochloride
|
Cytotoxicity against rat L6 cells assessed as inhibition of cell viability incubated for 24 hrs by MTT assay
Cytotoxicity against rat L6 cells assessed as inhibition of cell viability incubated for 24 hrs by MTT assay
|
[PMID: 32623216] |
| LoVo | IC50 |
89 μM
Compound: 1
|
Antitumor activity against human LoVo cells after 5 days by MTT assay
Antitumor activity against human LoVo cells after 5 days by MTT assay
|
[PMID: 19595598] |
| MC3T3-E1 | IC50 |
120 μM
Compound: 1
|
Inhibition of mouse MC3T3-E1 cell proliferation after 48 to 72 hrs
Inhibition of mouse MC3T3-E1 cell proliferation after 48 to 72 hrs
|
[PMID: 19595598] |
| MCF-10A | IC50 |
>300 μM
Compound: Ciprofloxacin
|
Cytotoxicity against human MCF10A cells after 48 hrs by WST1 assay
Cytotoxicity against human MCF10A cells after 48 hrs by WST1 assay
|
[PMID: 24513049] |
| MCF7 | IC50 |
199 μM
Compound: 1
|
Inhibition of human MCF7 cell proliferation by MTT assay
Inhibition of human MCF7 cell proliferation by MTT assay
|
[PMID: 19595598] |
| MCF7 | IC50 |
476 μM
Compound: 1
|
Antitumor activity against human MCF7 cells after 5 days by MTT assay
Antitumor activity against human MCF7 cells after 5 days by MTT assay
|
[PMID: 19595598] |
| MCF7 | IC50 |
76 μM
Compound: 1
|
Inhibition of human MCF7 cell proliferation after 5 days by MTT assay
Inhibition of human MCF7 cell proliferation after 5 days by MTT assay
|
[PMID: 19595598] |
| MCF7 | CC50 |
60 μg/mL
Compound: Ciprofloxacin
|
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay
|
[PMID: 27720324] |
| MCF7 | IC50 |
>100 μM
Compound: Ciprofloxacin
|
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability by MTT assay
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability by MTT assay
|
[PMID: 30660827] |
| MCF7 | IC50 |
>128 μM
Compound: CFX
|
Anticancer activity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
Anticancer activity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
|
[PMID: 31881454] |
| MCF7 | IC50 |
8.85 μM
Compound: C; Cip
|
Antitumor activity against human MCF7 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
Antitumor activity against human MCF7 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
|
[PMID: 34319100] |
| MG-63 | IC50 |
150 μg/mL
Compound: Ciprofloxacin
|
Inhibition of metabolic activity in MG63 cells assessed as MTT reduction after 48 hrs
Inhibition of metabolic activity in MG63 cells assessed as MTT reduction after 48 hrs
|
[PMID: 17088489] |
| MG-63 | IC50 |
160 μg/mL
Compound: Ciprofloxacin
|
Antiproliferative effect against MG63 cells assessed as BrdU incorporation into DNA after 48 hrs after 48 hrs
Antiproliferative effect against MG63 cells assessed as BrdU incorporation into DNA after 48 hrs after 48 hrs
|
[PMID: 17088489] |
| MG-63 | IC50 |
480 μM
Compound: 1
|
Inhibition of human MG63 cell proliferation assessed as bromodeoxyuridine incorporation during DNA synthesis after 48 hrs by ELISA
Inhibition of human MG63 cell proliferation assessed as bromodeoxyuridine incorporation during DNA synthesis after 48 hrs by ELISA
|
[PMID: 19595598] |
| MRC5 | IC50 |
53.4 μg/mL
Compound: CPF
|
Cytotoxicity against human MRC5 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Cytotoxicity against human MRC5 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 31431360] |
| MT4 | CC50 |
60 μM
Compound: Ciprofloxacin
|
Concentration required to reduce the viability of mock-infected MT-4 cells by 50%
Concentration required to reduce the viability of mock-infected MT-4 cells by 50%
|
[PMID: 10397494] |
| NCI-H460 | IC50 |
60 μM
Compound: 1
|
Inhibition of human NCI-H460 cell proliferation by sulphorodhamine B assay
Inhibition of human NCI-H460 cell proliferation by sulphorodhamine B assay
|
[PMID: 19595598] |
| NIH3T3 | IC50 |
>1000 μM
Compound: 1
|
Inhibition of mouse NIH/3T3 cell proliferation by MTT assay
Inhibition of mouse NIH/3T3 cell proliferation by MTT assay
|
[PMID: 19595598] |
| NIH3T3 | IC50 |
>200 μM
Compound: Ciprofloxacin
|
Cytotoxicity against mouse NIH/3T3 cells after 48 hrs by SRB assay
Cytotoxicity against mouse NIH/3T3 cells after 48 hrs by SRB assay
|
[PMID: 23711920] |
| NIH3T3 | IC50 |
305.77 μg/mL
Compound: Ciprofloxacin
|
Cytotoxicity against mouse NIH/3T3 cells assessed as reduction in cell proliferation after 24 hrs by MTT assay
Cytotoxicity against mouse NIH/3T3 cells assessed as reduction in cell proliferation after 24 hrs by MTT assay
|
[PMID: 28174104] |
| Osteoblast | IC50 |
>400 μg/mL
Compound: Ciprofloxacin
|
Inhibition of metabolic activity in primary human osteoblasts assessed as MTT reduction after 48 hrs
Inhibition of metabolic activity in primary human osteoblasts assessed as MTT reduction after 48 hrs
|
[PMID: 17088489] |
| Osteoblast | IC50 |
170 μg/mL
Compound: Ciprofloxacin
|
Antiproliferative effect against primary human osteoblasts assessed as BrdU incorporation into DNA after 48 hrs
Antiproliferative effect against primary human osteoblasts assessed as BrdU incorporation into DNA after 48 hrs
|
[PMID: 17088489] |
| PBMC | IC50 |
>0.5 mM
Compound: CPX, B-H
|
Cytotoxicity against human PBMC measured after overnight incubation by MTT assay
Cytotoxicity against human PBMC measured after overnight incubation by MTT assay
|
[PMID: 21855181] |
| PC-3 | IC50 |
143 μM
Compound: 1
|
Antitumor activity against human PC3 cells after 5 days by MTT assay
Antitumor activity against human PC3 cells after 5 days by MTT assay
|
[PMID: 19595598] |
| PC-3 | IC50 |
101.4 μM
Compound: CP
|
Antiproliferative activity against human PC3 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
Antiproliferative activity against human PC3 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
|
[PMID: 31678743] |
| SH-SY5Y | IC50 |
>0.5 mM
Compound: CPX, B-H
|
Cytotoxicity against human SH-SY5Y cells measured after overnight incubation by MTT assay
Cytotoxicity against human SH-SY5Y cells measured after overnight incubation by MTT assay
|
[PMID: 21855181] |
| SK-MEL | IC50 |
196 μM
Compound: 1
|
Inhibition of human SK-MEL cell proliferation by MTT assay
Inhibition of human SK-MEL cell proliferation by MTT assay
|
[PMID: 19595598] |
| SK-MEL3 | IC50 |
137 μM
Compound: Ciprofloxacin
|
Cytotoxicity against human SK-MEL-3 cells assessed as reduction in cell viability by MTT assay
Cytotoxicity against human SK-MEL-3 cells assessed as reduction in cell viability by MTT assay
|
[PMID: 30660827] |
| SK-MEL3 | IC50 |
>128 μM
Compound: CFX
|
Anticancer activity against human SK-MEL3 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
Anticancer activity against human SK-MEL3 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
|
[PMID: 31881454] |
| SMMC-7721 | IC50 |
≥ 100 μM
Compound: Ciprofloxacin
|
Antiproliferative activity against human SMMC7721 cells by MTT assay
Antiproliferative activity against human SMMC7721 cells by MTT assay
|
[PMID: 30660827] |
| SMMC-7721 | IC50 |
137 μM
Compound: Ciprofloxacin
|
Cytotoxicity against human SMMC7721 cells assessed as reduction in cell viability by MTT assay
Cytotoxicity against human SMMC7721 cells assessed as reduction in cell viability by MTT assay
|
[PMID: 30660827] |
| Splenocyte | IC50 |
>40 μM
Compound: CIPRO
|
Cytotoxicity against concanavalin-stimulated BALB/c mouse splenocytes after 72 hrs by resazurin dye reduction method
Cytotoxicity against concanavalin-stimulated BALB/c mouse splenocytes after 72 hrs by resazurin dye reduction method
|
[PMID: 19908867] |
| SW480 | IC50 |
128 μM
Compound: 1
|
Inhibition of human SW480 cell proliferation by MTT assay
Inhibition of human SW480 cell proliferation by MTT assay
|
[PMID: 19595598] |
| SW480 | IC50 |
137 μM
Compound: Ciprofloxacin
|
Cytotoxicity against human SW480 cells assessed as reduction in cell viability by MTT assay
Cytotoxicity against human SW480 cells assessed as reduction in cell viability by MTT assay
|
[PMID: 30660827] |
| SW480 | IC50 |
160.4 μM
Compound: CP
|
Antiproliferative activity against human SW480 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
Antiproliferative activity against human SW480 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
|
[PMID: 31678743] |
| SW480 | IC50 |
>128 μM
Compound: CFX
|
Anticancer activity against human SW480 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
Anticancer activity against human SW480 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
|
[PMID: 31881454] |
| SW-620 | IC50 |
200.4 μM
Compound: CP
|
Antiproliferative activity against human SW620 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
Antiproliferative activity against human SW620 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
|
[PMID: 31678743] |
| THP-1 | IC50 |
60.5 μM
Compound: Ciprofloxacin
|
Cytotoxicity against human THP1 cells assessed as cell viability after 72 hrs by MTT assay
Cytotoxicity against human THP1 cells assessed as cell viability after 72 hrs by MTT assay
|
[PMID: 24650715] |
| U-373MG ATCC | IC50 |
96 μM
Compound: 1
|
Antitumor activity against human U373MG cells after 5 days by MTT assay
Antitumor activity against human U373MG cells after 5 days by MTT assay
|
[PMID: 19595598] |
| V79 | IC50 |
>1000 μM
Compound: 1
|
Inhibition of chinese hamster V79 cell proliferation assessed as bromodeoxyuridine incorporation during DNA synthesis after 48 hrs by ELISA
Inhibition of chinese hamster V79 cell proliferation assessed as bromodeoxyuridine incorporation during DNA synthesis after 48 hrs by ELISA
|
[PMID: 19595598] |
| Vero | IC50 |
>188.5 μM
Compound: Ciprofloxacin
|
Cytotoxicity against african green monkey Vero cells after 72 hrs by MTT assay
Cytotoxicity against african green monkey Vero cells after 72 hrs by MTT assay
|
[PMID: 19131245] |
| Vero | CC50 |
600.8 μM
Compound: CPFX
|
Cytotoxicity against african green monkey Vero cells after 72 hrs by MTT assat
Cytotoxicity against african green monkey Vero cells after 72 hrs by MTT assat
|
[PMID: 21146257] |
| Vero | CC50 |
128 μg/mL
Compound: CPFX
|
Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability after 72 hrs by MTT assay
Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 30025351] |
| Vero | CC50 |
512 μg/mL
Compound: CPFX
|
Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability after 72 hrs by MTT assay
Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 30690301] |
| WI-38 | IC50 |
>100 μM
Compound: Ciprofloxacin
|
Antiproliferative activity against human WI38 cells after 24 hrs by BrdU incorporation assay
Antiproliferative activity against human WI38 cells after 24 hrs by BrdU incorporation assay
|
[PMID: 27555286] |
Ciprofloxacin (2.5-10 μg/mL; 24-72 h) preserves the stem cell-like spindle morphology of immortalized human dermal papilla cells, and concentrations of 5 and 10 μg/mL for 72 h significantly increase cell aggregation size and number[1].
Ciprofloxacin (10 μg/mL; 72 h) preserves CD133 stem cell marker expression and prevents increased procollagen type I fibroblast marker expression in immortalized human dermal papilla cells[1].
Ciprofloxacin (10 μg/mL; 24-72 h) prevents time-dependent loss of CD133, integrin β1, and ALDH1A1 stem cell markers and increases in procollagen type I fibroblast marker in immortalized human dermal papilla cells; concentrations of 2.5-10 μg/mL for 72 h modulate these markers in a dose-dependent manner[1].
Ciprofloxacin (2.5-10 μg/mL; 72 h) activates the Akt/GSK3β/β-catenin pathway in immortalized human dermal papilla cells in vitro in a dose-dependent manner, increasing activated Akt, inactivated GSK3β, and β-catenin levels[1].
Ciprofloxacin (2.5-10 μg/mL; 72 h) activates the Akt/GSK3β/β-catenin pathway and upregulates EMT transcription factors (ZEB1, Snail) in primary human dermal papilla cells in vitro in a dose-dependent manner[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Tendon cells
-
Concentration:5, 10, 20 and 50 μg/mL
-
Incubation Time:24 hours
-
Result:Decreased the cellularity of tendon cells.
-
Cell Line:Tendon cells
-
Concentration:50 μg/mL
-
Incubation Time:24 hours
-
Result:Arrested cell cycle at the G2/M phase and inhibited cell division in tendon cells.
-
Cell Line:Tendon cells
-
Concentration:50 μg/mL
-
Incubation Time:0, 6, 12, 17 and 24 hours
-
Result:Down-regulated the expression of CDK-1 and cyclin B protein and mRNA. Up-regulated the expression of PLK-1 protein.
-
Animal Model:BALB/c mice[3]
-
Dosage:30 mg/kg
-
Administration:Intraperitoneal injection; for 24 hours
-
Result:Reduced the lung bacterial load in murine model of pneumonic plague.
-
Animal Model:C57BL/6J mice[4]
-
Dosage:100 mg/kg
-
Administration:Oral gavage; daily, for 4 weeks
-
Result:Had aortic destruction that was accompanied by decreased LOX expression and increased MMP expression and activity.
-
Animal Model:C57BL/6J mice[4]
-
Dosage:100 mg/kg
-
Administration:Oral gavage; daily, for 4 weeks
-
Result:Caused mitochondrial DNA and nuclear DNA damage, leading to mitochondrial dysfunction and ROS production. Increased apoptosis and necroptosis in the aortic wall.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 93107-08-5
-
Appearance Solid
-
Masse moléculaire 367.81
-
Formule C17H19ClFN3O3
-
Color White to off-white
-
SMILES
[H]Cl.O=C(C1=CN(C2CC2)C3=C(C=C(F)C(N4CCNCC4)=C3)C1=O)O
-
Synonyms
Bay-09867 monohydrochloride
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
4°C, sealed storage, away from moisture and light
* The compound is unstable in solutions, freshly prepared is recommended.
Publications (57)
-
Journal Impact Factor
-
Most Recent
-
Nature
2024 Aug;632(8027):1137-1144. PMID: 39085612 -
-
Nat Cell Biol
2024 Sep;26(9):1545-1557. PMID: 38997456 -
Nat Commun
Antimicrobial resistance and population genomics of multidrug-resistant Escherichia coli in pig farms in mainland China. [Abstract]2022 Mar 2;13(1):1116. PMID: 35236849 -
Adv Sci (Weinh)
A Macromolecule Reversing Antibiotic Resistance Phenotype and Repurposing Drugs as Potent Antibiotics. [Abstract]2020 Jul 21;7(17):2001374. PMID: 32995131 -
Water Res
Variable cyanobacterial death modes caused by ciprofloxacin in the aquatic environment: Prioritizing antibiotic-photosynthetic protein interactions for risk assessment. [Abstract]2024 Nov 29:271:122885. PMID: 39642793
Ciprofloxacin monohydrochloride purchased from MedChemExpress. Usage Cited in: Water Res. 2024 Nov 29:271:122885. [Abstract]
Ciprofloxacin (CIP, 3 or 8 μg/L, 0-7 days) caused concentration-dependent damage in M. aeruginosa cells.
Ciprofloxacin monohydrochloride purchased from MedChemExpress. Usage Cited in: Water Res. 2024 Nov 29:271:122885. [Abstract]
Ciprofloxacin (CIP, 3 or 8 μg/L, 3 or 7 days) increased the release and decreased the biosynthesis of MC-LR in M. aeruginosa cells.
Ciprofloxacin monohydrochloride purchased from MedChemExpress. Usage Cited in: Water Res. 2024 Nov 29:271:122885. [Abstract]
Ciprofloxacin (CIP, 8 μg/L, 1 day) enriched gene ontology terms related to PSI in M. aeruginosa cells.
Ciprofloxacin monohydrochloride purchased from MedChemExpress. Usage Cited in: Water Res. 2024 Nov 29:271:122885. [Abstract]
Ciprofloxacin (CIP, 3 or 8 μg/L, 21 days) induced continuous cell lysis, with maximum lytic rates of ∼70% compared to the initial cell density.
Ciprofloxacin monohydrochloride purchased from MedChemExpress. Usage Cited in: Water Res. 2024 Nov 29:271:122885. [Abstract]
Ciprofloxacin (CIP, 3 or 8 μg/L, 1, 3, 5, or 7 days) induced cell death in M. aeruginosa.
-
Water Res
Quantifying community-wide antibiotic usage via urban water fingerprinting: Focus on contrasting resource settings in South Africa. [Abstract]2023 Jul 15:240:120110. PMID: 37247434 -
Ciprofloxacin monohydrochloride purchased from MedChemExpress. Usage Cited in: Chem Eng J. 2025 May 1.
The number of surviving bacteria after 24 h of treatment with free Ciprofloxacin monohydrochloride or Ciprofloxacin monohydrochloride-loaded liposomes at 658 a 3 μg/mL of Ciprofloxacin monohydrochloride concentration.
Ciprofloxacin monohydrochloride purchased from MedChemExpress. Usage Cited in: Chem Eng J. 2025 May 1.
The CI values for 660 antibacterial efficacy of blank liposomes and Ciprofloxacin monohydrochloride.
-
J Exp Med
2026 Mar 2;223(3):e20241287. PMID: 41400657 -
NPJ Biofilms Microbiomes
Echinacoside reduces intracellular c-di-GMP levels and potentiates tobramycin activity against Pseudomonas aeruginosa biofilm aggregates. [Abstract]2025 Mar 7;11(1):40. PMID: 40055321 -
NPJ Biofilms Microbiomes
Gut microbiota dysbiosis-mediated ceramides elevation contributes to corticosterone-induced depression by impairing mitochondrial function. [Abstract]2024 Oct 28;10(1):111. PMID: 39468065 -
EBioMedicine
A novel inhibitor of monooxygenase reversed the activity of tetracyclines against tet(X3)/tet(X4)-positive bacteria. [Abstract]2022 Apr;78:103943. PMID: 35306337 -
Genome Biol
Caloric restriction remodels the hepatic chromatin landscape and bile acid metabolism by modulating the gut microbiota. [Abstract]2023 Apr 30;24(1):98. PMID: 37122023 -
Food Res Int
Prevalence, plasmid transmission, and chromosomal integration of blaCTX-M genes in Salmonella isolated from retail chicken and pork meats in China. [Abstract]2026 Aug 31:238:119421. PMID: 42215089 -
-
Arch Pharm Res
Cell membrane chromatography relative competitive method for the accurate determination of relative KD values of drug-receptor interactions. [Abstract]2025 Jan;48(1):102-114. PMID: 39658753 -
J Med Chem
Design, Synthesis, and Biological Evaluation of Mono- and Diamino-Substituted Squaramide Derivatives as Potent Inhibitors of Mycobacterial Adenosine Triphosphate (ATP) Synthase. [Abstract]2025 Dec 11;68(23):25274-25289. PMID: 41277442 -
Virulence
Antibacterial efficacy and mechanism of the novel antimicrobial peptide lachnospirin-1 against Acinetobacter baumannii. [Abstract]2026 Dec 31;17(1):2646808. PMID: 41838520 -
Virulence
Bactericidal and anti-quorum sensing activity of repurposing drug Visomitin against Staphylococcus aureus. [Abstract]2024 Dec;15(1):2415952. PMID: 39390774 -
J Agric Food Chem
2025 Dec 23. PMID: 41436099 -
Anal Chim Acta
A natural fluorescent protein for ciprofloxacin sensing and mechanism study using molecular docking and circular dichroism. [Abstract]2022 Aug 15:1221:340082. PMID: 35934392 -
Front Microbiol
Enrofloxacin Promotes Plasmid-Mediated Conjugation Transfer of Fluoroquinolone-Resistance Gene qnrS. [Abstract]2022 Feb 16:12:773664. PMID: 35250901 -
-
-
Ciprofloxacin monohydrochloride purchased from MedChemExpress. Usage Cited in: ACS Appl Polym Mater. 2023 Aug 29.
Representative TEM images of blank micelles (BM) and Ciprofloxacin monohydrochloride-loaded micelles (CM) formulated in 1× PBS at pH 7.4.
Ciprofloxacin monohydrochloride purchased from MedChemExpress. Usage Cited in: ACS Appl Polym Mater. 2023 Aug 29.
Cumulative ciprofloxacin release from Ciprofloxacin monohydrochloride-loaded micelles over 72 h with an inset of the release over the first 12 h at pH 4.4 (red) and pH 7.4 (gray).
Ciprofloxacin monohydrochloride purchased from MedChemExpress. Usage Cited in: ACS Appl Polym Mater. 2023 Aug 29.
Cumulative Ciprofloxacin monohydrochloride release at 12 and 72 h.
-
Molecules
2023 Jun 8;28(12):4628. PMID: 37375183 -
Int J Antimicrob Agents
Activity of TP-6076 against carbapenem-resistant Acinetobacter baumannii isolates collected from inpatients in Greek hospitals. [Abstract]2018 Aug;52(2):269-271. PMID: 29559273 -
PLoS Pathog
Differential contribution of PBP occupancy and efflux on the effectiveness of β-lactams at their target site in clinical isolates of Neisseria gonorrhoeae. [Abstract]2024 Dec 31;20(12):e1012783. PMID: 39739989 -
Appl Microbiol Biotechnol
2022 Apr;106(7):2689-2702. PMID: 35338386 -
iScience
Analysis of microbiota reveals the underlying mechanism of PHF11 in the development of Enterococcus-regulated endometriotic cysts. [Abstract]2023 Oct 7;26(11):108158. PMID: 37915596 -
Antimicrob Agents Chemother
Stepwise evolution and clonal enrichment of gepotidacin resistance in Neisseria gonorrhoeae. [Abstract]2026 Apr;70(4):e0170625. PMID: 41810969 -
Antimicrob Agents Chemother
An enoyl-ACP reductase inhibitor, NITD-916, expresses anti- Mycobacterium abscessus activity. [Abstract]2025 Jul 2;69(7):e0024925. PMID: 40407337 -
J Antimicrob Chemother
Harnessing metabolic dependence-driven antibiotic synergy to eradicate tolerant Pseudomonas aeruginosa. [Abstract]2026 Jun 3;81(7):dkag204. PMID: 42267541 -
Microbiol Spectr
Antimicrobial resistance of rapidly growing mycobacteria isolated from companion animals in Taiwan. [Abstract]2025 Jul;13(7):e0307424. PMID: 40387379 -
Microbiol Spectr
Phenotypic and Genotypic Characterization of Multidrug-Resistant Enterobacter hormaechei Carrying qnrS Gene Isolated from Chicken Feed in China. [Abstract]2022 Jun 29;10(3):e0251821. PMID: 35467399 -
Microbiol Spectr
The Mechanism of Action of Ginkgolic Acid (15:1) against Gram-Positive Bacteria Involves Cross Talk with Iron Homeostasis. [Abstract]2022 Feb 23;10(1):e0099121. PMID: 35019708 -
J Antimicrob Chemother
In vitro activity of the novel β-lactamase inhibitor taniborbactam (VNRX-5133), in combination with cefepime or meropenem, against MDR Gram-negative bacterial isolates from China. [Abstract]2020 Jul 1;75(7):1850-1858. PMID: 32154866 -
Microb Pathog
Bacitracin-resistant Staphylococcus aureus induced in chicken gut and in vitro under bacitracin exposure. [Abstract]2024 Jun:191:106666. PMID: 38685360 -
Appl Biochem Biotechnol
Evaluation of Benzothiazole-Chalcone Hybrids: Apoptosis Induction, Docking Analysis, and Anticancer Potential in Gastric Cancer Cells. [Abstract]2025 Aug 23. PMID: 40848211 -
-
Cardiovasc Toxicol
Ciprofloxacin Accelerates Angiotensin-II-Induced Vascular Smooth Muscle Cells Senescence Through Modulating AMPK/ROS pathway in Aortic Aneurysm and Dissection. [Abstract]2024 Sep;24(9):889-903. PMID: 39138741 -
-
Infect Drug Resist
In vitro Activity of the Novel Tetracyclines Derivative, Zifanocycline Against Mycobacterium abscessus. [Abstract]2025 Oct 4:18:5239-5247. PMID: 41069760 -
Eur J Clin Microbiol Infect Dis
Evaluation of EUCAST rapid antimicrobial susceptibility testing (RAST) for carbapenemase-producing Klebsiella pneumoniae with focus on KPC variants. [Abstract]2025 Sep 29. PMID: 41023358 -
Anim Dis
Pasteurella multocida capsular: lipopolysaccharide types D:L6 and A:L3 remain to be the main epidemic genotypes of pigs in China. [Abstract]2021;1(1):26. PMID: 34778886 -
Vet Microbiol
Discovery of the tigecycline resistance gene cluster tmexCD3-toprJ1 in Pasteurella multocida strains isolated from pigs in China. [Abstract]2024 May:292:110046. PMID: 38471428 -
J Microbiol Methods
Comparison of agar-based and checkerboard methods to assess phage-antimicrobial synergy in Pseudomonas aeruginosa. [Abstract]2026 Feb 25:107441. PMID: 41759663 -
Diagn Microbiol Infect Dis
2026 Feb;114(2):117181. PMID: 41205476 -
-
-
-
-
-
-
-
-
Chemosphere
Mass-balance-model-based evaluation of sewage treatment plant contribution to residual pharmaceuticals in environmental waters. [Abstract]2019 Jun:225:378-387. PMID: 30884299
Solvant et solubilité
H2O : 12.5 mg/mL (33.98 mM; Need ultrasonic)
DMSO : 5 mg/mL (13.59 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 0.5 mg/mL (1.36 mM); Clear solution
This protocol yields a clear solution of ≥ 0.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (5.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * The compound is unstable in solutions, freshly prepared is recommended.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (280 KB)
-
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Kiratipaiboon C, et al. Ciprofloxacin Improves the Stemness of Human Dermal Papilla Cells. Stem Cells Int. 2016;2016:5831276. [Content Brief]
[3]. Kamocki K, et al. Effects of ciprofloxacin-containing antimicrobial scaffolds on dental pulp stem cell viability-In vitro studies. Arch Oral Biol. 2015;60(8):1131-1137. [Content Brief]
[4]. Ilgin S, et al. Ciprofloxacin-induced neurotoxicity: evaluation of possible underlying mechanisms. Toxicol Mech Methods. 2015;25(5):374-381. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO / H2O | 1 mM | 2.7188 mL | 13.5940 mL | 27.1880 mL | 67.9699 mL |
| 5 mM | 0.5438 mL | 2.7188 mL | 5.4376 mL | 13.5940 mL | |
| 10 mM | 0.2719 mL | 1.3594 mL | 2.7188 mL | 6.7970 mL | |
| H2O | 15 mM | 0.1813 mL | 0.9063 mL | 1.8125 mL | 4.5313 mL |
| 20 mM | 0.1359 mL | 0.6797 mL | 1.3594 mL | 3.3985 mL | |
| 25 mM | 0.1088 mL | 0.5438 mL | 1.0875 mL | 2.7188 mL | |
| 30 mM | 0.0906 mL | 0.4531 mL | 0.9063 mL | 2.2657 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.